| Company Name: |
Manhag Testing Technology Co., Ltd
|
| Tel: |
400-818 0104 18918165978 |
| Email: |
zilin.ren@bestown.net.cn |
| Products Intro: |
Product Name:Obeticholic Acid-[d4]
Purity:1mg Package:1mg
|
| Company Name: |
Reer Technology (Shanghai) Co., LTD
|
| Tel: |
021-64400900 15800436310 |
| Email: |
bessey@reertech.com |
| Products Intro: |
Product Name:OBETICHOLIC ACID(2,2,4,4-D4, 98%)
CAS:2025364-15-0
Purity:98% Package:1 MG Remarks:DLM-10618-0.001
|
| Company Name: |
CHINA ISOTOPE CO., LIMITED
|
| Tel: |
02151600108 13062666369 |
| Email: |
info@isotopechem.com |
| Products Intro: |
Product Name:6-ECDCA-d4
CAS:2025364-15-0
Purity:Purity: >=98% Package:1mg Remarks:CA39007
|
| Company Name: |
Shanghai Beiwanta Biotechnology Co., Ltd.
|
| Tel: |
021-67187366 19901745723 |
| Email: |
info@bwtlab.com |
| Products Intro: |
Product Name:Obeticholic Acid-[d4
CAS:2025364-15-0
Purity:99% Package:1mg;5mg;10mg;50mg
|
|
| | Obeticholic Acid-[d4] Basic information |
| | Obeticholic Acid-[d4] Chemical Properties |
| solubility | DMSO: Sparingly soluble: 1-10 mg/ml
Ethanol: Sparingly soluble: 1-10 mg/ml | | form | Solid | | color | White to off-white |
| | Obeticholic Acid-[d4] Usage And Synthesis |
| Uses | 6-ECDCA-d4 (6α-ethyl Cheodeoxycholic Acid-d4, Obeticholic Acid-d4) is deuterium labeled 6-ECDCA[1]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] ROBERTO PELLICCIARI. 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity[J]. Journal of Medicinal Chemistry, 2002, 45 17: 3569-3572. DOI: 10.1021/jm025529g
[3] STEFANO FIORUCCI. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.[J]. Journal of Pharmacology and Experimental Therapeutics, 2005, 313 2: 604-612. DOI: 10.1124/jpet.104.079665
[4] STEFANO FIORUCCI. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.[J]. ACS Applied Electronic Materials, 2005: 584-595. DOI: 10.1124/jpet.105.084905
[5] GIOVANNI RIZZO. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.[J]. Molecular Pharmacology, 2006, 70 4: 1164-1173. DOI: 10.1124/mol.106.023820
[6] SHINOBU MIYAZAKI-ANZAI. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.[J]. Circulation research, 2010, 106 12: 1807-1817. DOI: 10.1161/circresaha.109.212969 |
| | Obeticholic Acid-[d4] Preparation Products And Raw materials |
|